• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Down0.16% Nasdaq Down0.08%

    More On BLRX

    BioLineRx, Ltd. (BLRX)

    2.50 Down 0.15(5.66%) Jul 2, 4:00PM EDT
    Add to Portfolio
    ProfileGet Profile for:
    BioLineRx, Ltd.
    19 Hartum Street
    PO Box 9777518
    Jerusalem, 91450
    Israel - Map
    Phone: 972 2 548 9100
    Fax: 972 2 548 9101
    Website: http://www.biolinerx.com

    Index Membership:N/A
    Full Time Employees:46

    Business Summary 

    BioLineRx Ltd., a clinical stage biopharmaceutical development company, engages in identifying, in-licensing, and developing therapeutic candidates that address unmet medical needs. The company’s development pipeline consists of clinical-stage therapeutic candidates, including BL-1040, a novel polymer solution for use in the prevention of ventricular remodeling following an acute myocardial infarction; BL-8040, a novel peptide for the treatment of acute myeloid leukemia, stem cell mobilization, and other hematological indications; BL-7010, a novel polymer for the treatment of celiac disease; BL-5010, a medical device for the non-surgical removal of benign skin lesions; BL-7040, an oligonucleotide for the treatment of inflammatory bowel disease; and BL-8020, an orally available treatment for the hepatitis C virus and other viral indications. It also has four therapeutic candidates in the preclinical stages of development, including BL-8030 for the treatment of Hepatitis C; BL-9010 to treat severe allergies and asthma; BL-9020 for the treatment of type 1 diabetes; and BL-1110 for the treatment of neuropathic pain and scleroderma. The company has strategic collaboration with Novartis Pharma AG for the co-development of drug candidates. BioLineRx Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on BioLineRx, Ltd.

    Key Executives 
    Dr. Kinneret Livnat Savitzky Ph.D., 48
    Chief Exec. Officer
    Mr. Philip A. Serlin CPA, MBA, 54
    Chief Operating Officer, Chief Financial Officer, Principal Accounting Officer and Member of Investment Monitoring Committee
    Dr. Leah Klapper Ph.D., 50
    Chief Scientific Officer
    Mr. David Malek MBA, 37
    VP of Bus. Devel.
    Dr. Arnon Aharon M.D., 46
    VP of Medical Affairs
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in USD.